FluoGuide (FLOU) Investing in Life Science 2025 summary

Product innovation and clinical progress

• Developed a uPAR-targeted imaging agent that lights up cancer during surgery, aiding precision and reducing recurrence risk.

• Proven efficacy in lung, head and neck, and brain cancers, with orphan drug designation in the U.S.

• Product is equipment-independent, compatible with major imaging and surgical platforms.

• Over 100 patients in clinical trials have tolerated the product well, with no long-term toxicity observed.

• Interim phase II data and additional partnerships are expected soon.

Regulatory and market strategy

• Strong feedback from FDA, with a robust primary endpoint for clinical trials.

• IND filing planned by year-end, with a 40-patient study using gross total resection as the endpoint.

• U.S. market prioritized due to higher pricing and more qualified regulatory feedback; Europe to follow, focusing on large markets.

• Non-exclusive agreements with major equipment manufacturers like Intuitive Surgical and Olympus to maximize market reach.

• Pricing expected at $5,000 per treatment in the U.S., slightly lower in Europe, aligning with current market alternatives.

Competitive positioning and future outlook

• Differentiated by equipment independence, broad applicability across solid cancers, and high safety profile.

• Market potential estimated at 45 million procedures globally, with near-term focus on 9 million highly relevant cases.

• Enabling surgery in more complex cancer locations, expanding the addressable market.

• Plans to further penetrate the market and de-risk development through additional partnerships and clinical milestones.

• Future development may include therapeutic applications with higher pricing potential.